Cargando…

Efficacy of Sequential Capecitabine on Adjuvant Chemotherapy of Triple-Negative Breast Cancer

This paper aims to evaluate the efficacy of capecitabine as extended adjuvant treatment after anthracycline and paclitaxel combined adjuvant chemotherapy for women with early triple-negative breast cancer (TNBC). The patients with early TNBC were randomly assigned to capecitabine sequential treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xi, Xun, Huang, Xingwei, Yuan, Huozhong, Ni, Jun, Yang, Fulan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901322/ https://www.ncbi.nlm.nih.gov/pubmed/35265304 http://dx.doi.org/10.1155/2022/7430775

Ejemplares similares

Efficacy and Safety of Capecitabine for Triple-Negative Breast Cancer: A Meta-Analysis
por: Xun, Xueqiong, et al.
Publicado: (2022)

Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients
por: de Boo, Leonora W., et al.
Publicado: (2022)

The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis
por: Huo, Xingfa, et al.
Publicado: (2021)

The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis
por: Zhang, Zilin, et al.
Publicado: (2021)

Capecitabine-based chemotherapy in early-stage triple-negative breast cancer: a meta-analysis
por: Bai, Jie, et al.
Publicado: (2023)

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
por: Lluch, Ana, et al.
Publicado: (2020)

Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
por: Asleh, Karama, et al.
Publicado: (2023)

The Assessment of Response to Adjuvant Chemotherapy with CMF in Triple Negative Breast Cancer
por: Mousavi, Seyyed AsadoLah, et al.
Publicado: (2013)

Effectiveness of adjuvant chemotherapy for elderly patients with triple-negative breast cancer
por: Guo, Qiusheng, et al.
Publicado: (2023)

Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience
por: Vetter, Marcus, et al.
Publicado: (2017)

Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer
por: Bhattacharyya, G. S., et al.
Publicado: (2018)

Genetic variations in triple-negative breast cancers undergoing neo-adjuvant chemotherapy
por: Mori, Miki, et al.
Publicado: (2019)

Association of Adjuvant Chemotherapy With Overall Survival Among Women With Small, Node-Negative, Triple-Negative Breast Cancer
por: Oladeru, Oluwadamilola T., et al.
Publicado: (2020)

Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial
por: Li, Junjie, et al.
Publicado: (2020)

Addition of Capecitabine to Adjuvant Chemotherapy May be the Most Effective Strategy for Patients With Early-Stage Triple-Negative Breast Cancer: A Network Meta-Analysis of 9 Randomized Controlled Trials
por: Li, Zhiyang, et al.
Publicado: (2022)

Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer
por: Ding, Feng, et al.
Publicado: (2022)

Anti-transcriptional intermediary factor-1γ antibody-positive dermatomyositis in a patient with triple-negative breast cancer treated with adjuvant capecitabine
por: Kessler, Alaina J., et al.
Publicado: (2023)

Accuracy of MRI for prediction of response to neo-adjuvant chemotherapy in triple negative breast cancer
por: Bansal, GJ, et al.
Publicado: (2015)

Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics
por: Gámez-Pozo, Angelo, et al.
Publicado: (2017)

Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study
por: Li, Yi-Hui, et al.
Publicado: (2018)

The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer
por: Lim, Seung Taek, et al.
Publicado: (2018)

The Effect of Neoadjuvant vs Adjuvant Chemotherapy on Final Outcome of Patients with Triple Negative Breast Cancer
por: Dabbagh, Najmeh, et al.
Publicado: (2022)

Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis
por: Petrelli, Fausto, et al.
Publicado: (2022)

Clinical efficacy of local targeted chemotherapy for triple-negative breast cancer
por: He, Jinsong, et al.
Publicado: (2011)

Triple-Negative Breast Cancer: Adjuvant Therapeutic Options
por: Gucalp, Ayca, et al.
Publicado: (2011)

The advance of adjuvant treatment for triple-negative breast cancer
por: Ge, Jingyu, et al.
Publicado: (2022)

Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials
por: Ye, Feng, et al.
Publicado: (2022)

Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy
por: Montagna, Emilia, et al.
Publicado: (2020)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

Polymorphisms in AURKA and AURKB are associated with the survival of triple-negative breast cancer patients treated with taxane-based adjuvant chemotherapy
por: Liao, Yuqian, et al.
Publicado: (2018)

Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer
por: Tang, Yiqing, et al.
Publicado: (2012)

FPA-FTIR Microspectroscopy for Monitoring Chemotherapy Efficacy in Triple-Negative Breast Cancer
por: Zawlik, Izabela, et al.
Publicado: (2016)

Adjuvant treatment for triple negative breast cancer with residual tumor after neo-adjuvant chemotherapy. A single institutional retrospective analysis
por: Bianco, Nadia, et al.
Publicado: (2021)

Metronomic chemotherapy for triple negative breast cancer?
por: Di Desidero, Teresa, et al.
Publicado: (2016)

PTHrP, A Biomarker for CNS Metastasis in Triple-Negative Breast Cancer and Selection for Adjuvant Chemotherapy in Node-Negative Disease
por: Assaker, Gloria, et al.
Publicado: (2019)

Capecitabine in adjuvant radiochemotherapy for gastric adenocarcinoma
por: Oblak, Irena, et al.
Publicado: (2014)

A study of the efficacy and tolerability of capecitabine and lobaplatin in advanced HER-2 negative breast cancer patients
por: Yuan, Yuan, et al.
Publicado: (2021)

Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer
por: Pitts, Todd M., et al.
Publicado: (2020)

Docetaxel, Oxaliplatin and Capecitabine (TEX) triplet regimen as adjuvant chemotherapy in resected gastric adenocarcinoma
por: Thumaty, Divya Bala, et al.
Publicado: (2021)

Cost-effectiveness analysis of metronomic capecitabine as adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma
por: She, Longjiang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g9ur4va3dlt5d61viuqs466t8c